| AWARE-AMAC (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation in Asia pacific, Middle-east and African Countries (AWARE-AMAC): A noninterventional study to collect data on the management and clinical impacts of chronic urticaria in patients refractory to H1-antihistamine therapy |
Ongoing |
N/A |
4 |
E3401 |
King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah) |
| Postoperative Analgesic Effect ofDexmedetomidine as an Adjunct to Ropivacaine Administration in Wound Infiltration for Modified Radical Mastectomy- A Randomized controlled Trial |
Ongoing |
DEXMEDETOMIDINE |
2 |
14-119 |
King Abdullah Medical City (Makkah) |
| CogniPlus Study assessing Cognitive performance plus Physical activity in patients with Relapsing-Remitting MS under treatment with Betaferon® |
Ongoing |
Betaferon |
4 |
16036 |
King Fahad Hospital (Madinah), Security Forces Hospital (Riyadh), Aseer Central Hospital, King Khalid University Hospital (Riyadh), Al-Noor Specialist Hospital (Makkah), King Abdul Aziz Specialist hospital (Taif), King Fahad Specialist Hospital (Dammam) |
| Non transfusion dependent Thalassemia Drug Registry |
Ongoing |
Exjade (Deferasirox) |
4 |
E2422 |
King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Jeddah), King Khalid University Hospital (Riyadh) |
| A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer |
Ongoing |
LEE011 (Ribociclib) |
3 |
CLEE011E2301 |
King Khalid University Hospital (Riyadh)_ King Faisal Specialist Hospital and Research Center (Riyadh) |
| International Registry to assess mEdical Practice withlOngitudinal obseRvation for Treatment of Heart Failure(REPORT-HF) |
Ongoing |
N/A |
4 |
2401 |
King Fahad Specialist Hospital (Dammam) |
| Phase IIIb, Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness & Safety of the use of Carbaglu® in Patients with Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA) |
Ongoing |
Carglumic acid |
3 |
IIT-OE-2013-001 |
King Abdulaziz Medical City NG (Riyadh)_ King Fahad Medical City (Riyadh) |
| A Randomized, Multi-Center Study to Evaluate Cardiovascular Outcomes With ITCA 650 in Patients Treated With Standard of Care for Type 2 Diabetes |
Completed |
ITCA 650 |
3 |
ITCA 650-CLP-107 |
King Abdulaziz Medical City NG (Jeddah)_ King Abdulaziz Hospital NG (Al Ahsa) |
| A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer |
Ongoing |
Sorafenib |
3 |
BAY43-9006/14295 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis |
Ongoing |
Purified Poloxamer 188 |
3 |
MST-188-01 |
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh), Maternity and Children's Hospital (Al Ahsa)_ King Fahad Medical City (Riyadh)_ King Abdulaziz University Hospital (Jeddah) |
